Literature DB >> 35084549

Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.

Wanru Duan1,2, Boyan Zhang1, Xinqiang Li3, Wei Chen4, Shanhang Jia1, Zong Xin1, Qiang Jian1, Fengzeng Jian1,2, Dean Chou5, Zan Chen6,7.   

Abstract

Chordoma is a rare and aggressive bone tumor. An accurate investigation of tumor heterogeneity is necessary for the development of effective therapeutic strategies. This study aims to assess the poorly understood tumor heterogeneity of chordomas and identify potential therapeutic targets. Single-cell RNA sequencing was performed to delineate the transcriptomic landscape of chordomas. Six tumor samples of chordomas were obtained, and 33,737 cells passed the quality control test and were analyzed. The main cellular populations identified with specific markers were as follows: chordoma cells (16,052 [47.6%]), fibroblasts (6945 [20.6%]), mononuclear phagocytes (4734 [14.0%]), and T/natural killer (NK) cells (3944 [11.7%]). Downstream analysis of each cell type was performed. Six subclusters of chordomas exhibited properties of an epithelial-like extracellular matrix, stem cells, and immunosuppressive activity. Although few immune checkpoints were detected on cytotoxic immune cells such as T and NK cells, a strong immunosuppressive effect was exerted on the Tregs and M2 macrophages. In addition, the cellular interactions were indicative of enhancement of the TGF-β signaling pathway being the main mechanism for tumor progression, invasion, and immunosuppression. These findings, especially from the analysis of molecular targeted therapy and tumor immune microenvironment, may help in the identification of therapeutic targets in chordomas.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Chordomas; Cytotoxic immune cells; Immunosuppressive activity; Single-cell RNA sequencing

Mesh:

Year:  2022        PMID: 35084549     DOI: 10.1007/s00262-022-03152-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  52 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

Review 2.  Chordoma: current concepts, management, and future directions.

Authors:  Brian P Walcott; Brian V Nahed; Ahmed Mohyeldin; Jean-Valery Coumans; Kristopher T Kahle; Manuel J Ferreira
Journal:  Lancet Oncol       Date:  2012-02       Impact factor: 41.316

Review 3.  Single-cell RNA sequencing for the study of development, physiology and disease.

Authors:  S Steven Potter
Journal:  Nat Rev Nephrol       Date:  2018-08       Impact factor: 28.314

Review 4.  Tumour heterogeneity and resistance to cancer therapies.

Authors:  Ibiayi Dagogo-Jack; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2017-11-08       Impact factor: 66.675

5.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Authors:  Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel
Journal:  Lancet Oncol       Date:  2017-10-04       Impact factor: 41.316

6.  Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).

Authors:  E Bompas; A Le Cesne; E Tresch-Bruneel; L Lebellec; V Laurence; O Collard; E Saada-Bouzid; N Isambert; J Y Blay; E Y Amela; S Salas; C Chevreau; F Bertucci; A Italiano; S Clisant; N Penel
Journal:  Ann Oncol       Date:  2015-07-22       Impact factor: 32.976

7.  Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review.

Authors:  Tong Meng; Jiali Jin; Cong Jiang; Runzhi Huang; Huabin Yin; Dianwen Song; Liming Cheng
Journal:  Front Oncol       Date:  2019-02-01       Impact factor: 6.244

Review 8.  Advances in immune checkpoint inhibitors for bone sarcoma therapy.

Authors:  Pichaya Thanindratarn; Dylan C Dean; Scott D Nelson; Francis J Hornicek; Zhenfeng Duan
Journal:  J Bone Oncol       Date:  2019-01-29       Impact factor: 4.072

Review 9.  Epigenetic heterogeneity in cancer.

Authors:  Mingzhou Guo; Yaojun Peng; Aiai Gao; Chen Du; James G Herman
Journal:  Biomark Res       Date:  2019-10-31

10.  The driver landscape of sporadic chordoma.

Authors:  Patrick S Tarpey; Sam Behjati; Matthew D Young; Inigo Martincorena; Ludmil B Alexandrov; Sarah J Farndon; Charlotte Guzzo; Claire Hardy; Calli Latimer; Adam P Butler; Jon W Teague; Adam Shlien; P Andrew Futreal; Sohrab Shah; Ali Bashashati; Farzad Jamshidi; Torsten O Nielsen; David Huntsman; Daniel Baumhoer; Sebastian Brandner; Jay Wunder; Brendan Dickson; Patricia Cogswell; Josh Sommer; Joanna J Phillips; M Fernanda Amary; Roberto Tirabosco; Nischalan Pillay; Stephen Yip; Michael R Stratton; Adrienne M Flanagan; Peter J Campbell
Journal:  Nat Commun       Date:  2017-10-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.